The LUGPA Alternative Payment Model for Initial Therapy of Newly Diagnosed Patients With Organ-confined Prostate Cancer: Rationale and Development.
The LUGPA Alternative Payment Model for Initial Therapy of Newly Diagnosed Patients With Organ-confined Prostate Cancer: Rationale and Development.
复制标题
DOI：
10.3909/riu0779
复制
发表时间：
2017-01-01
期刊：
影响因子：
--
通讯作者：
Latino, Kathleen
中科院分区：
文献类型：
--
作者：
Kapoor, Deepak A;Shore, Neal D;Latino, Kathleen
在过去的几十年里，医疗支出的快速增长暴露了按服务付费模式固有的利用激励。2015年《医疗保险准入和芯片再授权法案》的通过预示着向基于价值的护理过渡，为从业者接受与结果和利用指标相关的双向风险创造了激励。目前，这些工具的有限可用性排除了除少数供应商之外的所有供应商参与替代支付模式（APM）。LUGPA APM支持三重目标的目标，即改善患者体验，增强人口健康和减少支出。通过要求使用经认证的电子健康记录技术，将付款与质量指标挂钩，并要求实践承担超过名义风险，LUGPA APM有资格成为先进的APM，从而减轻报告负担并为参与实践创造机会。
Over the past several decades, rapid expansion in healthcare expenditures has exposed the utilization incentives inherent in fee-for-service payment models. The passage of Medicare Access and CHIP Reauthorization Act of 2015 heralded a transition toward value-based care, creating incentives for practitioners to accept bidirectional risk linked to outcome and utilization metrics. At present, the limited availability of these vehicles excludes all but a handful of providers from participation in alternative payment models (APMs). The LUGPA APM supports the goals of the triple aim in improving the patient experience, enhancing population health and reducing expenditures. By requiring utilization of certified electronic health record technologies, tying payment to quality metrics, and requiring practices to bear more than nominal risk, the LUGPA APM qualifies as an advanced APM, thereby easing the reporting burden and creating opportunities for participating practices.